Lexicon Pharmaceuticals | LXRX - Créances Commerciales





Créances Commerciales Changement Date
Abbott USD 10.57B 171M 2025-12
Acadia Pharmaceuticals USD 148.23M 8.79M 2025-12
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Akebia Therapeutics USD 47.03M 19.19M 2025-12
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
AstraZeneca USD 17.88B 1.17B 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Coherus Biosciences USD 18.42M 232.08M 2025-12
Eli Lilly USD 21.18B 1.02B 2026-03
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Halozyme Therapeutics USD 441.27M 95.24M 2025-12
Illumina USD 738M 116M 2026-03
Insmed USD 140.86M 75.6M 2025-12
Ironwood Pharmaceuticals USD 81.89M 5.68M 2024-12
J&J USD 21.33B 3.72B 2025-12
Lexicon Pharmaceuticals USD 2.38M 50K 2025-12
MacroGenics USD 13.37M 55.86M 2025-12
MannKind USD 38.37M 20.98M 2025-12
Merck USD 11.78B 345M 2025-12
Moderna USD 71M 113M 2026-03
Novartis USD 9.6B 2.69B 2026-03
PTC Therapeutics USD 181.62M 21.45M 2025-12
Puma Biotechnology USD 28.1M 3.52M 2024-06
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
Thermo Fisher Scientific USD 9.2B 304M 2026-03
Ultragenyx Pharmaceutical USD 158M 45.46M 2025-12
United Therapeutics USD 350.2M 52.5M 2025-12
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12